Rates of COVID-19-Associated Hospitalization in Immunocompromised Individuals in Omicron-era: A Population-Based Observational Study Using Surveillance Data in British Columbia, Canada
Bahremand, T.; Yao, J. A.; Mill, C.; Piszczek, J.; Grant, J. M.; Smolina, K.
Show abstract
BackgroundPeople with immune dysfunction have a higher risk for severe COVID-19 outcomes. Omicron variant is associated with a lower rate of hospitalization but higher vaccine escape. This population-based study quantifies COVID-19 hospitalization rate in the Omicron-dominant era among vaccinated people with immune dysfunction, identified as clinically extremely vulnerable (CEV) population before COVID-19 treatment was widely offered. MethodsAll COVID-19 cases were reported to the British Columbia Centre for Disease Control (BCCDC) between January 7, 2022 and March 14, 2022. Case and population hospitalization rates were estimated across CEV status, age groups and vaccination status. Cumulative rates of hospitalizations for the study period were also compared between CEV and non-CEV individuals matched by sex, age group, region, and vaccination characteristics. FindingsA total of 5,591 COVID-19 reported cases and 1,153 hospitalizations among CEV individuals were included. A third vaccine dose with mRNA vaccine offered additional protection against severe illness in CEV individuals. Vaccinated CEV population still had a significantly higher breakthrough hospitalization rate compared with non-CEV individuals. InterpretationCEV population remains a higher risk group and may benefit from additional booster doses and pharmacotherapy. FundingBC Centre for Disease Control and Provincial Health Services Authority
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study 95%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada 95%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 95%
Similar papers in this journal
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 95%
- Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages 95%
- Vaccine-induced antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by delta and omicron variants: a prospective observational cohort study 93%
Similar papers in this journal
Similar papers in this journal
- Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study 96%
- Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020–May 2021 94%
- Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study 94%
Similar papers in this journal
- Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults 95%
- Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities 95%
- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February – May 2021 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.